Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...
Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...
Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...
When a sickle cell pain crisis landed her in the hospital, columnist Mary Shaniqua soon identified the cause: getting two vaccines at once.
Mary Shaniqua is a sickle cell patient (HbSS) living in the United Kingdom. She was diagnosed with sickle cell at 18 months old and uses “Shaniqua’s Sickle Chronicles” to narrate her experiences, to ...
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback